Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: LCTX (3-star) is a SELL. SELL since 4 days. Simulated Profits (25.78%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.17
1 Year Target Price $4.17
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.81% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 396.16M USD | Price to earnings Ratio - | 1Y Target Price 4.17 |
Price to earnings Ratio - | 1Y Target Price 4.17 | ||
Volume (30-day avg) 7 | Beta 1.78 | 52 Weeks Range 0.37 - 2.09 | Updated Date 12/6/2025 |
52 Weeks Range 0.37 - 2.09 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.02 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -102.85% |
Management Effectiveness
Return on Assets (TTM) -13.65% | Return on Equity (TTM) -157.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 349085262 | Price to Sales(TTM) 36.63 |
Enterprise Value 349085262 | Price to Sales(TTM) 36.63 | ||
Enterprise Value to Revenue 32.27 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 230327537 | Shares Floating 171425876 |
Shares Outstanding 230327537 | Shares Floating 171425876 | ||
Percent Insiders 5.38 | Percent Institutions 41.17 |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics Inc. (formerly Geron Corporation's regenerative medicine business) was spun out and rebranded in 2017. It is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company's key technology platforms are designed to produce differentiated cells for therapeutic applications. Significant milestones include the progression of its lead product candidates through clinical trials and strategic partnerships.
Core Business Areas
- Allogeneic Cell Therapy Development: Lineage Cell Therapeutics focuses on developing off-the-shelf cell therapies derived from pluripotent stem cells. These therapies aim to replace or repair damaged tissues and organs. The company's core competency lies in its proprietary cell manufacturing processes that allow for scalable and consistent production of therapeutic cells.
- Product Pipeline: The company has a pipeline of product candidates in various stages of clinical development targeting diseases with significant unmet medical needs, including neurological disorders, ophthalmological diseases, and oncology.
Leadership and Structure
Lineage Cell Therapeutics Inc. is led by a management team with expertise in biotechnology, regenerative medicine, and business development. The organizational structure is typical of a clinical-stage biotech company, with dedicated departments for research and development, clinical operations, regulatory affairs, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- OPC1 (OpRegen): A progenitor cell therapy designed to treat spinal cord injury. It aims to promote remyelination and neuronal regeneration. Currently in clinical trials. Competitors in the spinal cord injury regenerative medicine space include companies exploring stem cell therapies and other novel approaches, though direct head-to-head market share data is not readily available due to the early-stage nature of the field.
- LCT-104 (Immuncell): A cancer immunotherapy candidate derived from natural killer (NK) cells. It is designed to target and eliminate cancer cells. It is in preclinical and early clinical development. Competitors include numerous companies developing CAR-T therapies, other NK cell-based therapies, and various forms of immunotherapy for cancer treatment.
- RNAi-based therapeutics: Lineage Cell Therapeutics also has collaborations and research programs exploring RNA interference (RNAi) technologies for various indications, though these are generally in earlier stages.
Market Dynamics
Industry Overview
The regenerative medicine and cell therapy market is a rapidly growing and dynamic sector within the broader biotechnology industry. It is characterized by significant scientific innovation, high research and development costs, and a complex regulatory landscape. The market is driven by the potential to treat chronic and debilitating diseases that currently have limited therapeutic options.
Positioning
Lineage Cell Therapeutics Inc. is positioned as a clinical-stage company with a proprietary platform for developing allogeneic cell therapies. Its competitive advantage lies in its ability to manufacture differentiated cells at scale and its focus on well-defined therapeutic targets in areas of high unmet medical need. However, as a clinical-stage company, it faces the inherent risks associated with drug development and regulatory approval.
Total Addressable Market (TAM)
The total addressable market for cell therapies is substantial and growing, encompassing a wide range of diseases including neurological disorders, cardiovascular diseases, diabetes, and cancer. While specific TAM figures vary depending on the indication, the potential market for conditions like spinal cord injury or various cancers is in the billions of dollars. Lineage Cell Therapeutics Inc. is positioned to capture a portion of this TAM with its pipeline candidates, but its current market penetration is minimal as it is still in the clinical development phase.
Upturn SWOT Analysis
Strengths
- Proprietary cell manufacturing technology enabling scalable production.
- Experienced management team with expertise in regenerative medicine.
- Pipeline of novel cell therapy candidates targeting significant unmet medical needs.
- Allogeneic approach offers potential for off-the-shelf availability.
- Strategic partnerships and collaborations.
Weaknesses
- Clinical-stage company with no approved products, leading to high development risk.
- Significant capital requirements for R&D and manufacturing.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Competition from established pharmaceutical companies and other emerging biotech firms.
- Manufacturing complexity and potential for batch variability.
Opportunities
- Growing demand for innovative treatments for chronic and degenerative diseases.
- Advancements in stem cell biology and gene editing technologies.
- Expansion into new therapeutic indications and geographic markets.
- Potential for licensing agreements and partnerships.
- Increasing investor interest in the cell and gene therapy sector.
Threats
- Clinical trial failures or adverse events.
- Regulatory hurdles and delays in drug approval.
- Intense competition and emergence of disruptive technologies.
- Reimbursement challenges for novel therapies.
- Economic downturns impacting investment in biotech.
Competitors and Market Share
Key Competitors
- Geron Corporation (GERN)
- Mesoblast Limited (MESO)
- Sangamo Therapeutics, Inc. (SGMO)
- CRISPR Therapeutics AG (CRSP)
Competitive Landscape
Lineage Cell Therapeutics Inc. operates in a highly competitive landscape with other companies developing cell and gene therapies. Its advantages include its proprietary manufacturing technology and focus on allogeneic therapies, which offer potential advantages in scalability and accessibility compared to autologous treatments. However, it faces challenges from larger, more established companies with greater financial resources and broader portfolios, as well as from other innovative biotech firms developing similar or competing technologies.
Growth Trajectory and Initiatives
Historical Growth: Historically, Lineage Cell Therapeutics Inc.'s growth has been characterized by the advancement of its scientific platform and clinical pipeline. This includes securing funding, conducting preclinical studies, initiating and progressing clinical trials, and establishing strategic collaborations.
Future Projections: Future growth projections are contingent on the successful development and commercialization of its product candidates. Analyst expectations typically focus on potential market penetration of its lead programs and future licensing or partnership opportunities. Significant revenue and profitability are not expected until products gain regulatory approval and market access.
Recent Initiatives: Recent initiatives may include the initiation of new clinical trials, progress updates on existing trials, strategic partnerships, and efforts to expand manufacturing capabilities or explore new therapeutic applications for its cell therapy platforms.
Summary
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company with a promising allogeneic cell therapy platform. Its strengths lie in its proprietary manufacturing and a pipeline targeting significant unmet medical needs. However, it faces substantial risks associated with clinical development and regulatory approval. Continued success hinges on positive clinical trial outcomes and effective capital management in a highly competitive biotech landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- SEC Filings (10-K, 10-Q)
- Industry Analyst Reports
- Biotechnology News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is illustrative and not based on precise, up-to-the-minute tracking, as the cell therapy market is nascent and highly fragmented.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.